SKB BIO - VOLUNTARY ANNOUNCEMENT NEW INDICATION APPLICATION FOR CORE PRODUCT TROP2 ADC SACITUZUMAB TIRUMOTECAN (sac-TMT) ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

the Board and non-executive Director, Dr. GE Junyou as executive Director, Mr. LIU Sichuan,

Mr. LAI Degui, Mr. FENG Hao, Ms. LIAO Yihong and Mr. ZENG Xuebo as non-executive Directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping and Dr. LI Yuedong as independent non-executive Directors.

1 KEYTRUDA® (pembrolizumab) is a registered trademark of Merck Sharp & Dohme LLC (MSD), a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

– 3 –